Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Corticosteroid to Prevent Epiretinal Membrane Formation
NCT02412059Completed
- Sponsor
- Unity Health Toronto
- Start
- Aug 2015
- Primary completion
- Jan 2016
- Modality
- Orthosteric Ligands
01
Overview
Randomised, double-blind trial of prednisolone in epiretinal membrane (ERM) (2 arms), sponsored by Unity Health Toronto. Primary endpoint: Incidence of epiretinal membrane at 6 months. Started Aug 2015; status: completed.
02
Drugs
prednisolone
03
Conditions
epiretinal membrane (ERM)
Beyond the preview
Go deeper on NCT02412059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412059.